Literature DB >> 26064267

Compatibility of Astragalus and Salvia extract inhibits myocardial fibrosis and ventricular remodeling by regulation of protein kinase D1 protein.

Bingyu Mao1, Liu Nuan1, Lei Yang1, Xiaotao Zeng2.   

Abstract

AIMS: This study is to determine the effect of astragalus and salvia extract on the alteration of myocardium in a rat model of myocardial infarction.
METHODS: A total of 40 male Sprague-Dawley rats were randomly divided into the sham-operated group, the control group, the Astragalus group, the Salvia group, and the compatibility of Astragalus and Salvia and group. The cardiac functions were determined at 8 weeks after treatment. Hematoxylin-eosin staining was performed to observe the morphology and arrangement of cardiomyocytes. Masson's trichrome staining was performed to investigate the distribution of myocardial interstitial collagen. Immunohistochemical staining was performed to determine the expression ofprotein kinase D1 in myocardial tissues.
RESULTS: In the sham-operated group, the Astragalus group, the Salvia group, and the compatibility of Astragalus and Salvia group, the left ventricular systolic pressure and the maximum rate of left ventricular pressure were significantly increased while the left ventricular end diastolic pressure were significantly decreased when compared with those in the control group (P < 0.05). Normal morphology and arrangement of cardiomyocytes were maintained in the compatibility of Astragalus and Salvia group. Contents of collagen fibers in myocardial tissues were decreased in the compatibility of Astragalus and Salvia group (P < 0.05). Expression levels of protein kinase D1 were significantly decreased in cardiomyocytes of the compatibility of Astragalus and Salvia group.
CONCLUSIONS: Compatibility of Astragalus and Salvia extract may inhibit myocardial fibrosis and ventricular remodeling by regulation of protein kinase D1 protein in a rat model of myocardial infarction.

Entities:  

Keywords:  Astragalus; compatibility; myocardial infarction; protein kinase D; salvia

Year:  2015        PMID: 26064267      PMCID: PMC4443101     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  14 in total

1.  Phospholipase Cε hydrolyzes perinuclear phosphatidylinositol 4-phosphate to regulate cardiac hypertrophy.

Authors:  Lianghui Zhang; Sundeep Malik; Jinjiang Pang; Huan Wang; Keigan M Park; David I Yule; Burns C Blaxall; Alan V Smrcka
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

2.  Identification of a novel phosphorylation site in c-jun directly targeted in vitro by protein kinase D.

Authors:  Richard T Waldron; Julian P Whitelegge; Kym F Faull; Enrique Rozengurt
Journal:  Biochem Biophys Res Commun       Date:  2007-03-05       Impact factor: 3.575

Review 3.  Oxidative stress and left ventricular remodelling after myocardial infarction.

Authors:  Masatsugu Hori; Kazuhiko Nishida
Journal:  Cardiovasc Res       Date:  2008-12-01       Impact factor: 10.787

4.  Protein kinase D selectively targets cardiac troponin I and regulates myofilament Ca2+ sensitivity in ventricular myocytes.

Authors:  Friederike Cuello; Sonya C Bardswell; Robert S Haworth; Xiaoke Yin; Susanne Lutz; Thomas Wieland; Manuel Mayr; Jonathan C Kentish; Metin Avkiran
Journal:  Circ Res       Date:  2007-02-22       Impact factor: 17.367

5.  AKAP13 Rho-GEF and PKD-binding domain deficient mice develop normally but have an abnormal response to β-adrenergic-induced cardiac hypertrophy.

Authors:  Matthew J Spindler; Brian T Burmeister; Yu Huang; Edward C Hsiao; Nathan Salomonis; Mark J Scott; Deepak Srivastava; Graeme K Carnegie; Bruce R Conklin
Journal:  PLoS One       Date:  2013-04-26       Impact factor: 3.240

6.  Identifying roles of "Jun-Chen-Zuo-Shi" component herbs of QiShenYiQi formula in treating acute myocardial ischemia by network pharmacology.

Authors:  Leihong Wu; Yi Wang; Zheng Li; Boli Zhang; Yiyu Cheng; Xiaohui Fan
Journal:  Chin Med       Date:  2014-09-16       Impact factor: 5.455

Review 7.  Effects of fibrosis morphology on reentrant ventricular tachycardia inducibility and simulation fidelity in patient-derived models.

Authors:  Jordan Ringenberg; Makarand Deo; David Filgueiras-Rama; Gonzalo Pizarro; Borja Ibañez; Rafael Peinado; José L Merino; Omer Berenfeld; Vijay Devabhaktuni
Journal:  Clin Med Insights Cardiol       Date:  2014-09-25

8.  Level and significance of plasma myeloperoxidase and the neutrophil to lymphocyte ratio in patients with coronary artery disease.

Authors:  Fadia A Mayyas; Mohammad I Al-Jarrah; Khalid S Ibrahim; Karem H Alzoubi
Journal:  Exp Ther Med       Date:  2014-10-17       Impact factor: 2.447

Review 9.  Molecular basis of cardioprotective effect of antioxidant vitamins in myocardial infarction.

Authors:  Ramón Rodrigo; Matías Libuy; Felipe Feliú; Daniel Hasson
Journal:  Biomed Res Int       Date:  2013-07-14       Impact factor: 3.411

10.  A network pharmacology study of Chinese medicine QiShenYiQi to reveal its underlying multi-compound, multi-target, multi-pathway mode of action.

Authors:  Xiang Li; Leihong Wu; Wei Liu; Yecheng Jin; Qian Chen; Linli Wang; Xiaohui Fan; Zheng Li; Yiyu Cheng
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

View more
  5 in total

Review 1.  Insights of Chinese medicine on ventricular remodeling: Multiple-targets, individualized-treatment.

Authors:  Dan-Cai Fan; Jian-Yong Qi; Min-Zhou Zhang
Journal:  Chin J Integr Med       Date:  2017-09-02       Impact factor: 1.978

Review 2.  Effect of Traditional Chinese Medicine on the Cardiovascular Diseases.

Authors:  Yang Jiang; Qi Zhao; Lin Li; Shumin Huang; Shuai Yi; Zhixi Hu
Journal:  Front Pharmacol       Date:  2022-03-21       Impact factor: 5.810

3.  Astragalus Membranaceus Improving Asymptomatic Left Ventricular Diastolic Dysfunction in Postmenopausal Hypertensive Women with Metabolic Syndrome: A Prospective, Open-Labeled, Randomized Controlled Trial.

Authors:  Ning-Yin Li; Heng Yu; Xiu-Li Li; Qiong-Ying Wang; Xiao-Wei Zhang; Rui-Xin Ma; Yang Zhao; Han Xu; Wei Liang; Feng Bai; Jing Yu
Journal:  Chin Med J (Engl)       Date:  2018-03-05       Impact factor: 2.628

4.  Shensong Yangxin capsule reduces atrial fibrillation susceptibility by inhibiting atrial fibrosis in rats with post-myocardial infarction heart failure.

Authors:  Jin Ma; Chunxia Yin; Shiyu Ma; Huiliang Qiu; Chaoyang Zheng; Qiuxiong Chen; Chunhua Ding; Weihui Lv
Journal:  Drug Des Devel Ther       Date:  2018-10-10       Impact factor: 4.162

Review 5.  Overview of Salvia miltiorrhiza as a Potential Therapeutic Agent for Various Diseases: An Update on Efficacy and Mechanisms of Action.

Authors:  Inyong Jung; Hyerin Kim; Seongcheol Moon; Hyuk Lee; Bonglee Kim
Journal:  Antioxidants (Basel)       Date:  2020-09-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.